Advertisement

Topics

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017

06:00 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
INBRIJA™ (levodopa inhalation powder) NDA resubmitted in December 2017 AMPYRA 4Q 2017 Net Sales of $167 million; Full Year 2017 Net Sales of $543 million 2017 year-end cash and cash equ...

Other Sources for this Article

Acorda Therapeutics, Inc.
Felicia Vonella, 914-326-5146
fvonella@acorda.com

NEXT ARTICLE

More From BioPortfolio on "Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...